Standard BioTools Inc. (LAB)
1.35
-0.04 (-2.88%)
At close: Feb 20, 2025, 3:59 PM
1.35
-0.37%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 1.33 |
| Market Cap | 504.41M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -1.96 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.48 |
| Volume | 1,915,266 |
| Avg. Volume (20D) | 1,675,513 |
| Open | 1.39 |
| Previous Close | 1.39 |
| Day's Range | 1.33 - 1.41 |
| 52-Week Range | 1.17 - 3.04 |
| Beta | undefined |
About LAB
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immu...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Feb 10, 2011
Employees 534
Stock Exchange NASDAQ
Ticker Symbol LAB
Website https://www.fluidigm.com
Analyst Forecast
According to 2 analyst ratings, the average rating for LAB stock is "Buy." The 12-month stock price forecast is $2.88, which is an increase of 112.55% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Standard BioTools Inc. is scheduled to release its earnings on Feb 26, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+26.38%
Standard BioTools shares are trading higher after ...
Unlock content with
Pro Subscription
6 months ago
-36.61%
Standard BioTools shares are trading lower after the company reported worse-than-expected Q2 financial results and cut FY24 revenue guidance below estimates. The company announced CFO Jeffery Black will resign.
